Lanean...
The age of enlightenment in melanoma immunotherapy
An updated survival analysis by Callahan et al. published in the February 1, 2018 issue of the Journal of Clinical Oncology reported a 3-year overall survival (OS) rate of 63% for 94 patients with previously treated or untreated advanced melanoma who received ipilimumab and nivolumab as concurrent t...
Gorde:
| Argitaratua izan da: | J Immunother Cancer |
|---|---|
| Egile nagusia: | |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6103975/ https://ncbi.nlm.nih.gov/pubmed/30134977 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0397-8 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|